Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome.
Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics in patients with GTS. It can be hypothesized that these beneficial effects are related to aripiprazole's adaptive pharmacological profile, which exhibits an influence on the dopaminergic as well as a number of other neurotransmitter systems. For the first time, our data provide evidence that patients' decision making process for or against medical treatment is influenced by other factors than tic severity and QoL.
Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School Hannover, Germany.
Sarah
S
Gerasch
Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical SchoolHannover, Germany; Max Planck Institute for Human Cognitive and Brain SciencesLeipzig, Germany.
Ahmad Seif
AS
Kanaan
Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School Hannover, Germany.
Ewgeni
E
Jakubovski
Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School Hannover, Germany.
Kirsten R
KR
Müller-Vahl
ADHD; OCD; Tourette Syndrome; anxiety; aripiprazole; depression; premonitory urge; quality of life
Mov Disord. 1999 May;14(3):502-6
10348478
Brain. 2000 Mar;123 Pt 3:425-62
10686169
Dev Med Child Neurol. 2000 Jul;42(7):436-47
10972415
J Autism Dev Disord. 2001 Feb;31(1):5-17
11439754
Lancet. 2002 Nov 16;360(9345):1577-86
12443611
Nervenarzt. 2003 Nov;74(11):987-93
14598035
Nervenarzt. 2004 Sep;75(9):888-95
15378249
J Clin Psychopharmacol. 2005 Feb;25(1):94-6
15643108
Braz J Psychiatry. 2004 Sep;26(3):213
15645072
Am J Psychiatry. 2005 Mar;162(3):625
15741488
Int J Neuropsychopharmacol. 2005 Sep;8(3):489-90
15857570
J Dev Behav Pediatr. 2005 Dec;26(6):397-403
16344654
Prim Care Companion J Clin Psychiatry. 2005;7(6):296-9
16498492
Brain. 2006 Aug;129(Pt 8):2029-37
16520330
Ann Pharmacother. 2006 Apr;40(4):775-7
16569800
World J Biol Psychiatry. 2006;7(2):123-5
16684686
Int J Neuropsychopharmacol. 2006 Dec;9(6):773-4
16734937
J Child Neurol. 2006 Apr;21(4):358
16900939
J Child Adolesc Psychopharmacol. 2006 Aug;16(4):505-6
16958578
Eur Arch Psychiatry Clin Neurosci. 2006 Sep;256 Suppl 1:i3-11
16977549
Hum Psychopharmacol. 2006 Oct;21(7):447-53
17029306
J Clin Psychiatry. 2007 Jul;68(7):1088-93
17685747
Psychol Med. 2008 Feb;38(2):289-300
17922940
Mov Disord. 2008 Feb 15;23(3):438-40
18067182
CNS Drugs. 2008;22(5):367-88
18399707
J Child Adolesc Psychopharmacol. 2008 Apr;18(2):197-205
18439116
J Clin Psychopharmacol. 2008 Aug;28(4):441-6
18626272
J Clin Psychopharmacol. 2008 Aug;28(4):452-4
18626274
World J Biol Psychiatry. 2009;10(4 Pt 3):827-31
18843565
J Child Adolesc Psychopharmacol. 2008 Oct;18(5):509-15
18928415
J Clin Psychol. 2008 Dec;64(12):1338-51
18942133
Neurology. 2008 Oct 28;71(18):1410-6
18955683
World J Biol Psychiatry. 2009;10(4 Pt 3):977-80
19225990
J Child Adolesc Psychopharmacol. 2009 Aug;19(4):441-7
19702496
Int J Neuropsychopharmacol. 2009 Oct;12(9):1291-3
19706223
J Child Adolesc Psychopharmacol. 2009 Dec;19(6):623-33
20035580
Mov Disord. 2010 Feb 15;25(3):309-14
20063404
Z Kinder Jugendpsychiatr Psychother. 2010 Jul;38(4):291-8
20617499
Eur Psychiatry. 2011 Mar;26(2):100-7
20619613
J Child Adolesc Psychopharmacol. 2010 Aug;20(4):291-8
20807067
Curr Treat Options Neurol. 2010 Nov;12(6):539-61
20848326
PLoS One. 2010 Sep 24;5(9):e12959
20885982
J Affect Disord. 2011 Jan;128 Suppl 1:S11-20
21220076
Res Dev Disabil. 2011 May-Jun;32(3):924-38
21316190
Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96
21445724
Clin Pract Epidemiol Ment Health. 2011;7:107-11
21686322
Neurol Sci. 2011 Dec;32(6):1213-7
21732066
Cogn Neurosci. 2011 Sep;2(3-4):227-243
22299020
J Child Adolesc Psychopharmacol. 2012 Apr;22(2):120-5
22375853
Eur Child Adolesc Psychiatry. 2012 Aug;21(8):451-7
22543961
Depress Anxiety. 2012 Jun;29(6):523-30
22555849
J Clin Psychopharmacol. 2012 Aug;32(4):548-50
22722499
Neurosciences (Riyadh). 2012 Jul;17(3):200-4
22772923
J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):975-8
22842713
Arch Gen Psychiatry. 2012 Aug;69(8):795-803
22868933
BMC Psychiatry. 2012 Aug 13;12:109
22888766
Int J Neuropsychopharmacol. 2013 Apr;16(3):557-74
22932229
Depress Anxiety. 2012 Oct;29(10):850-4
22933237
Neurosci Biobehav Rev. 2013 Jul;37(6):1162-71
23099282
Neurosci Biobehav Rev. 2013 Jul;37(6):1157-61
23137552
J Psychiatr Res. 2013 Aug;47(8):1007-12
23664673
Curr Drug Saf. 2013 Jul;8(3):169-74
23914752
J Clin Psychiatry. 2013 Aug;74(8):e772-80
24021518
Behav Modif. 2014 Mar;38(2):264-75
24042069
Child Psychiatry Hum Dev. 2014 Oct;45(5):596-603
24343476
J Psychosom Res. 2014 Jun;76(6):472-6
24840142
Front Hum Neurosci. 2014 May 28;8:362
24904391
Braz J Med Biol Res. 2014 Jul;47(7):605-16
24919175
Qual Life Res. 2015 Apr;24(4):979-92
25281010
Ther Adv Psychopharmacol. 2015 Feb;5(1):32-7
25653829
JAMA Psychiatry. 2015 Apr;72(4):325-33
25671412
J Clin Psychopharmacol. 2015 Jun;35(3):350-1
25928702
Curr Pharm Des. 2015;21(23):3280-97
26088115
Psychiatry Res. 2015 Aug 30;228(3):765-73
26112450
CNS Drugs. 2015 Sep;29(9):773-99
26346901
Brain Dev. 2016 Feb;38(2):233-41
26360257
Tijdschr Psychiatr. 2015;57(8):579-87
26402894
Psychiatry Res. 2015 Dec 15;230(2):695-703
26548979
Acta Pol Pharm. 2015 May-Jun;72(3):597-606
26642668
J Atten Disord. 2016 Feb 2;:null
26838556
Arch Gen Psychiatry. 1989 Nov;46(11):1006-11
2684084
Chron Respir Dis. 2016 Aug;13(3):220-8
26944070
Front Neurosci. 2016 Sep 12;10:415
27672357
J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73
2768151
J Consult Clin Psychol. 1988 Dec;56(6):893-7
3204199
Br J Psychiatry. 1979 Apr;134:382-9
444788
Arch Gen Psychiatry. 1973 Jan;28(1):92-7
4509400
Am J Psychiatry. 1993 Jan;150(1):98-102
8417589
Am J Psychiatry. 1993 Jun;150(6):885-90
8494063
J Pers Assess. 1996 Dec;67(3):588-97
8991972
Neurol Clin. 1997 May;15(2):267-75
9115460